Matisse Pharmaceuticals is a biotechnology company dedicated to development of pharmaceutical therapies to treat disorders that are associated with fulminant inflammation such as sepsis. The most advanced product in development is the heparin fraction M6229 for the treatment of severe sepsis and septic shock.
Developing the solution to treat life-threatening inflammation
Septic shock is a leading cause of death and presents a major clinical problem in the intensive care unit. Common factor in septic patients is the high histone plasma level. Histones are toxic fragments released by diseased cells. The heparin fraction M6229 neutralizes histones offering a much better prognosis for the patient.
Matisse Pharmaceuticals is working closely together with several academic partners including the University of Maastricht, the Amsterdam Academic Medical Center and the Academic Medical Hospital of Uppsala